| No |
Study Code |
Journal |
Title |
Link |
| 141 |
KCSG BR15-17 |
Eur J Cancer. 2024 Jan:197:113456. |
Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): A randomized, open-label, multicenter, phase II trial |
|
| 140 |
KCSG LU19-04 |
J Clin Oncol. 2023 Oct 20:JCO2301891. Online ahead of print. |
Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04) |
|
| 139 |
KCSG HN15-16 |
J Clin Oncol. 2024 Feb 10;42(5):507-517. |
Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial |
|
| 138 |
KCSG UN14-13 |
Eur J Cancer . 2023 Nov:193:113312. doi: 10.1016/j.ejca.2023.113312. |
A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13) |
|
| 137 |
KCSG BR18-16 |
Eur J Cancer . 2023 Dec:195:113386. doi: 10.1016/j.ejca.2023.113386. |
Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16) |
|
| 136 |
KCSG LU19-04 |
J Clin Oncol . 2023 Oct 20 00:1-11 |
Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04) |
|
| 135 |
KCSG BR12-09 |
N Engl J Med 2021;385:2336-47. |
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer |
|
| 134 |
KCSG HN15-16 |
Cancer Res Treat . 2023 Jul 20. doi: 10.4143/crt.2023.433. |
A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC): In-Depth Analysis of Nintendanib Arm from the KCSG HN15-16 TRIUMPH Trial |
|
| 133 |
KCSG GU18-18 |
ESMO Open. 2023 Jun 27;8(4):101588. doi: 10.1016/j.esmoop.2023.101588 |
Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18. |
|
| 132 |
KCSG LY20-06 |
Korean J Intern Med. 2023 Sep;38(5):747-757. |
Treatment pattern of chronic lymphocytic leukemia/small lymphocytic lymphoma in Korea: a multicenter retrospective study (KCSG LY20-06). |
|
| 131 |
KCSG BR21-18 |
Oncologist. 2023 Dec 11;28(12):e1142-e1151. |
A Survey of Practice Patterns for Clinical Nodal Staging Prior to Neoadjuvant Chemotherapy in Breast Cancer |
|
| 130 |
KCSG RC20-09 |
Cancer Med. 2023 Jul;12(14):15159-15175. |
Treatment outcomes of advanced/metastatic extramammary Paget's disease in Korean patients: KCSG-RC20-06 |
|
| 129 |
KCSG ST13-10 |
Cancer Res Treat. 2023 May 25. |
A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10). |
|
| 128 |
KCSG ST18-20 |
Oncologist . 2023 Apr 10;oyad059. doi: 10.1093/oncolo/oyad059. Online ahead of print. |
AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20) |
|
| 127 |
KCSG UN18-05 |
Journal of Cancer Research and Therapeutics. April 04, 2023 |
Imatinib in c-KIT-mutated metastatic solid tumors: A multicenter trial of Korean Cancer Study Group (UN18-05 Trial) |
|
| 126 |
KCSG HN13-01 |
Cancers (Basel). 2023 Jan 12;15(2):471. |
Comparison of Treatment Patterns and Clinical Outcomes by Gender in Locally Advanced Head and Neck Squamous Cell Carcinoma (KCSG HN13-01) |
|
| 125 |
KCSG LU17-21 |
J Thorac Oncol. 2023 Feb;18(2):223-231. |
A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21) |
|
| 124 |
KCSG BR18-14 |
Breast. 2022 Oct;65:172-178. |
Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B) |
|
| 123 |
KCSG LU21-11 |
Clin Lung Cancer. 2022 Dec;23(8):e536-e539. |
A Multicenter Two-arm, Phase II Trial Assessing the Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (ABLATE, KCSG-LU21-11) |
|
| 122 |
KCSG BR07-03 |
Cancer Res Treat. 2022 Nov 8. doi: 10.4143/crt.2022.1360. Online ahead of print. |
A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03) |
|
| 121 |
KCSG PC21-20 |
Cancer Res Treat. 2022 Dec 27. |
Status of Using Complementary and Alternative Medicine among Patients with Cancer in Korea: an Online Survey of Online Cancer Support Groups (KCSG PC21-20) |
|
| 120 |
KCSG CO17-02 |
Clin Oncol (R Coll Radiol). 2023 Feb;35(2):e143-e152. |
Preoperative Chemoradiotherapy With Capecitabine With or Without Temozolomide in Patients With Locally Advanced Rectal Cancer: A Prospective, Randomised Phase II Study Stratified by O6-Methylguanine DNA Methyltransferase Status: KCSG-CO17-02 |
|
| 119 |
KCSG BR19-15/ ST19-16 |
Ther Adv Med Oncol 2022;14:1-13 |
Data collection framework for electronic medical record-based real-world data to evaluate the effectiveness and safety of cancer drugs: a nationwide real-world study of the Korean Cancer Study Group |
|
| 118 |
KCSG HB19-14 |
Lancet Gastroenterol Hepatol . 2023 Jan;8(1):56-65. |
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14) |
|
| 117 |
KCSG BR07-02 |
Breast Cancer Res Treat. 2015 Jul;152(1):77-85. |
Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02) |
|
| 116 |
KCSG PC17-01 |
Support Care Cancer. 2022 Sep;30(9):7431-7438. |
Discussing POLST facilitated hospice care enrollment in patients with terminal cancer. |
|
| 115 |
KCSG LU19-22 |
Transl Lung Cancer Res 2022;11(7):1369-1379 |
Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22 |
|
| 114 |
KCSG BR18-23 |
JAMA Oncol. 2022 Sep 1;8(9):1271-1277. |
Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial |
|
| 113 |
KCSG CO09-07 |
J Clin Oncol. 2022 Nov 20;40(33):3868-3877. |
Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07 |
|
| 112 |
KCSG HN17-11 |
Clin Cancer Res. 2022 Oct 3;28(19):4240-4247. |
A Phase II Study of Nivolumab Plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11) |
|
| 111 |
KCSG BR13-11 |
ESMO Open. 2021 Oct; 6(5): 100236. |
Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11) |
|
| 110 |
KCSG BR16-09 |
Cancer Res Treat. 2023 Jan;55(1):123-135. |
Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09) |
|
| 109 |
KCSG LU20-11 |
Cancer . 2022 Feb 15;128(4):778-787. |
Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11) |
|
| 108 |
KCSG HN13-01 |
Korean J Intern Med . 2022 Jan;37(1):190-200. |
Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01) |
|
| 107 |
NA |
J Cancer. 2022 Jan 1;13(3):869-876. |
Low PARP-1 expression level is an indicator of poor prognosis in patients with stage II and III gastric cancer |
|
| 106 |
KCSG ST19-16 |
Gastric Cancer. 2022 May;25(3):609-618. |
Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide,real-world study in Korea (KCSG-ST19-16) |
|
| 105 |
KCSG ST19-16 |
Ther Adv Med Oncol. 2021 Sep 18;13:17588359211042812. |
Ramucirumab plus paclitaxel as secondline treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16) |
|
| 104 |
KCSG LU19-05 |
J Cancer Res Clin Oncol. 2021 Aug;147(8):2459-2469. |
Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05 |
|
| 103 |
NA |
Cancer Res Treat. 2022 Jan;54(1):1-9 |
Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group |
|
| 102 |
NA |
Liver Int. 2022 Mar;42(3):674-681. |
Efficacy and safety atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma |
|
| 101 |
KCSG LU17-13 |
J Thorac Oncol. 2018 Sep;13(9):1373-1382. |
Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice |
|
| 100 |
KCSG HN14-06 |
Cancer Medicine. 2021 Oct;10(20):7012-7020 |
A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma |
|
| 99 |
KCSG LU13-05 |
BMC Cancer. 2021 Jul 12;21(1):802. |
An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitornaive patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations |
|
| 98 |
KCSG HN16-08 |
Clin Cancer Res. 2021 Oct 1;27(19):5272-5279. |
Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma |
|
| 97 |
KCSG HN13-01 |
Cancer Res Treat. 2022 Jan;54(1):109-117. |
Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: the Concept of Chemo-Selection (KCSG HN13-01) |
|
| 96 |
KCSG BR10-13 |
Cytokine. 2021 Jun;142:155487. |
Prognostic effects of cytokine levels on patients treated with taxane and zoledronic acid for metastatic breast cancer in bone (BEAT-ZO) (KCSG BR 10-13) |
|
| 95 |
NA |
ESMO Open. 2021 Apr;6(2):100049. |
Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG) |
|
| 94 |
KCSG PC13-09 |
Cancers (Basel). 2021 Jan 18;13(2):331. |
Prevalence and Predictive Factors for Upfront Dose Reduction of the First Cycle of First-Line Chemotherapy in Older Adults with Metastatic Solid Cancer: Korean Cancer Study Group (KCSG) Multicenter Study |
|
| 93 |
KCSG HN18-12 |
Cancer Res Treat. 2021 Jul;53(3):671-677. |
Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12 |
|
| 92 |
KCSG LU16-07 |
Thorac Cancer. 2020 Dec; 11(12): 3482-3489. |
Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07 |
|
| 91 |
KCSG BR15-10 |
Cancer Res Treat. 2021 Jul;53(3):695-702. |
Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL) |
|
| 90 |
KCSG HN18-12 |
J Cancer Res Clin Oncol. 2020 Dec;146(12):3359-3369 |
Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer
study group HN 18-12 |
|
| 89 |
KCSG HN12-12 |
Br J Cancer. 2020 Dec;123(12):1720-1729. |
Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck |
|
| 88 |
KCSG HN14-18 |
Cancer. 2020 Oct 15;126(20):4521-4531 |
Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma |
|
| 87 |
KCSG BR15-10 |
Cancers (Basel) . 2020 Nov 5;12(11):3265. |
Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine
in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10) |
|
| 86 |
KCSG UN17-16 |
Transl Cancer Res. 2020 May;9(5):3222-3230. |
Antitumor activity and safety of sirolimus for solid tumors with PIK3CA mutations: A multicenter, open-label, prospective single-arm study (KM 02-01, KCSG UN17-16) |
|
| 85 |
KCSG HN13-01 |
BMC Cancer. 2020 Aug 27;20(1):813 |
Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01) |
|
| 84 |
KCSG UN17-16 |
Mol Clin Oncol . 2017 Jul;7(1):27-31. |
Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer |
|
| 83 |
KCSG BR15-10 |
Lancet Oncol. 2019 Dec;20(12):1750-1759 |
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. |
|
| 82 |
KCSG PC13-09 |
Oncologist. 2020 Mar;25(3):e502-e511. |
Polypharmacy, Inappropriate Medication Use, and Drug Interactions in Older Korean Patients with Cancer Receiving First-Line Palliative Chemotherapy |
|
| 81 |
KCSG LU15-09 |
J Clin Oncol. 2020 Feb 10;38(5):488-495 |
Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations:
A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09) |
|
| 80 |
KCSG GU12-03 |
Cancer Res Treat. 2018 Apr;50(2):488-494 |
Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma:A Single-Arm, Open-Label, Multicenter, Phase II Study |
|
| 79 |
KCSG CO17-07 |
Cancer Res Treat. 2020 Oct;52(4):1135-1144. |
A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer |
|
| 78 |
KCSG PC14-17 |
Support Care Cancer. 2020 Nov;28(11):5177-5183 |
Interference with daily functioning by breakthrough pain in patients with cancer |
|
| 77 |
N/A |
Ther Adv Med Oncol. 2019 Aug 23;11:1758835919871126 |
Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group. |
|
| 76 |
KCSG GU10-16 |
Eur J Cancer. 2020 Mar;127:183-190 |
Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16) |
|
| 75 |
KCSG BR11-16 |
Br J Cancer. 2019 Dec;121(12):985-990. |
Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2+ metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16) |
|
| 74 |
KCSG PC17-01 |
Cancer Res Treat. 2019 Oct;51(4):1632-1638 |
Feasibility Study of Physician Orders for Life-Sustaining Treatment for Patients with Terminal Cancer |
|
| 73 |
KCSG PC13-09 |
J Geriatr Oncol. 2019 Sep;10(5):749-756 |
Serum biomarkers for predicting overall survival and early mortality in older patients with metastatic solid tumors |
|
| 72 |
KCSG BR13-11 |
Breast Cancer Res Treat. 2019 Nov;178(2):367-377 |
Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11). |
|
| 71 |
KCSG GU17-03 |
Cancer Med. 2019 Sep;8(12):5431-5437 |
Comparative effectiveness of palliative chemotherapy versus neoadjuvant chemotherapy followed by radical cystectomy versus cystectomy followed by adjuvant chemotherapy versus cystectomy for regional node-positive bladder cancer: A retrospective analysis: KCSG GU 17-03 |
|
| 70 |
KCSG ST13-10 |
Contemp Clin Trials Commun. 2017 Aug 18;8:55-61 |
Comparison of efficacy and tolerance between combination therapy and monotherapy as first-line chemotherapy in elderly patients with advanced gastric cancer: Study protocol for a randomized controlled trial |
|
| 69 |
KCSG ST06-01 |
J Cancer Res Clin Oncol. 2014 Feb;140(2):319-28 |
Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study(START) |
|
| 68 |
KCSG GU11-03 |
Cancer Res Treat. 2019 Oct;51(4):1578-1588 |
Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma |
|
| 67 |
KCSG ST10-01 |
Oncologist. 2019 Jan;24(1):18-e24. |
A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First-line Therapy (KCSG ST10-01) |
|
| 66 |
N/A |
Gastric Cancer. 2018 Sep;21(5):819-830. |
Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG) |
|
| 65 |
KCSG HN15-16 |
Cancer Res Treat. 2019 Jan; 51(1): 300-312. |
Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma |
|
| 64 |
KCSG BR10-04 |
Eur J Cancer. 2018 Nov;103:127-136. |
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study). |
|
| 63 |
KCSG LU12-13 |
Cancer Res Treat. 2019 Apr;51(2):718-726. |
A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13 |
|
| 62 |
KCSG PC13-02 |
Support Care Cancer. 2017 Dec;25(12):3759-3767. |
Multicenter, cross-sectional observational study of the impact of neuropathic pain on quality of life in cancer patients |
|
| 61 |
KCSG CO14-03 |
Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):889-899 |
A Randomized Phase II Trial of Consolidation Chemotherapy after Preoperative Chemoradiation versus Chemoradiation alone for Locally Advanced Rectal Cancer: KCSG CO 14-03 |
|
| 60 |
KCSG PC13-09 |
Br J Cancer.2018 May;118(9):1169-1175. |
Predicting cumulative incidence of adverse events in older patients with cancer undergoing first-line palliative chemotherapy: Korean Cancer Study Group (KCSG) multicentre prospective study. |
|
| 59 |
KCSG LU12-07 |
Br J Cancer. 2018 Mar 6;118(5):648-653. |
Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07). |
|
| 58 |
KCSG BR11-01 |
Cancer Res Treat. 2019 Jan;51(1):43-52. |
Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01). |
|
| 57 |
KCSG CO12-04 |
Korean J Intern Med. 2019 Jan;34(1):165-177. |
The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean
Cancer Study Group CO12-04 study. |
|
| 56 |
KCSG GU11-05 |
Cancer Res Treat. 2018 Oct;50(4):1252-1259. |
Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05). |
|
| 55 |
KCSG ST14-11 |
Gastric Cancer. 2018 Sep;21(5):802-810. |
Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11 |
|
| 54 |
KCSG BR13-11 |
Eur J Cancer. 2017 Nov;86:385-393. |
Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer |
|
| 53 |
KCSG LY16-01 |
Cancer Res Treat . 2018 Apr;50(2):590-598. |
Multicenter Retrospective Analysis of Clinical Characteristics, Treatment Patterns, and Outcomes in Very Elderly Patients with Diffuse Large B-Cell Lymphoma: The Korean Cancer Study Group LY16-01 |
|
| 52 |
KCSG LU13-08 |
J Clin Oncol. 2017 Aug 10;35(23):2613-2618 |
Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. |
|
| 51 |
KCSG GU14-08 |
Cancer Res Treat. 2016 Oct;48(4):1286-1292. |
Efficacy and Toxicity of Mammalian Target Rapamycin Inhibitors in Patients with Metastatic Renal Cell Carcinoma with Renal Insufficiency: The Korean Cancer Study Group GU 14-08 |
|
| 50 |
KCSG LU05-04 |
J Clin Oncol. 2015 Aug 20;33(24):2660-6. |
Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. |
|
| 49 |
KCSG 0806 |
Lung Cancer. 2016 Mar;93:1-8. |
A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806). |
|
| 48 |
KCSG PC10-09 |
Support Care Cancer. 2016 Apr;24(4):1709-17 |
A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09. |
|
| 47 |
KCSG HN14-01 |
Cancer. 2017 Jun 1;123(11):1958-1964. |
Clinical Trial of Nintedanib in Patients with Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck:A Multicenter Phase 2 Study (Korean Cancer Study Group HN14-01) |
|
| 46 |
KCSG HN12-02 |
Clin Cancer Res. 2015 Feb 1;21(3):544-52. |
Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck |
|
| 45 |
KCSG LU12-01 |
Oncotarget. 2017 Feb 28;8(9):15943-15951. |
A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) |
|
| 44 |
KCSG HN12-08 |
Eur J Cancer. 2015 Aug;51(12):1588-95. |
An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer |
|
| 43 |
KCSG HN13-06 |
Cancer Res Treat. 2017 Apr;49(2):416-422. |
Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer |
|
| 42 |
KCSG HN11-08 |
Clin Cancer Res. 2015 Feb 1;21(3):544-52. |
Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck |
|
| 41 |
KCSG PC10-21 |
Oncologist. 2015 Dec;20(12):1440-7. |
Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21 |
|
| 40 |
KCSG HN10-02 |
Radiother Oncol. 2016 Feb;118(2):244-50. |
Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02) |
|
| 39 |
KCSG HN10-03 |
Ann Oncol. 2013 Dec;24(12):3089-94 |
A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes. |
|
| 38 |
KCSG GY10-10 |
Gynecol Oncol. 2015 Feb;136(2):212-7 |
Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10 |
|
| 37 |
KCSG GU10-17 |
Br J Cancer. 2015 Jan 20;112(2):260-5 |
Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10-17). |
|
| 36 |
KCSG GU10-15 |
Br J Cancer. 2014 May 13;110(10):2472-8 |
Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed |
|
| 35 |
KCSG BR09-05 |
Ann Oncol. 2013 Jun;24(6):1485-90 |
Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905). |
|
| 34 |
KCSG LU08-01 |
Cancer. 2012 Dec 15;118(24):6234-42 |
Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial. |
|
| 33 |
KCSG HN07-01 |
Eur J Cancer. 2012 Nov;48(17):3198-204 |
A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01). |
|
| 32 |
KCSG BR07-02 |
J Clin Oncol. 2013 May 10;31(14):1732-9 |
Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. |
|
| 31 |
KCSG BR07-01 |
Breast Cancer Res Treat. 2012 Apr;132(2):589-600 |
Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: the Korean Cancer Study Group BR 07-01. |
|
| 30 |
KCSG HB07-01 |
Invest New Drugs . 2012 Jun;30(3):1164-74. |
A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research |
|
| 29 |
KCSG CO06-01 |
Am J Clin Oncol . 2013 Dec;36(6):565-71. |
Randomized phase II study of capecitabine with or without oxaliplatin as first-line treatment for elderly or fragile patients with metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group CO06-01. |
|
| 28 |
KCSG CO06-08 |
Am J Clin Oncol. 2014 Feb;37(1):19-23 |
A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group. |
|
| 27 |
KCSG ST06-13 |
Br J Cancer. 2009 Jan 27;100(2):298-304. |
Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. |
|
| 26 |
KCSG ST06-02 |
Cancer Chemother Pharmacol. 2012 Nov;70(5):665-72 |
A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02. |
|
| 25 |
KCSG LU06-04 |
Lung Cancer. 2009 Dec;66(3):338-43 |
Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: a prospective, multicenter trial. |
|
| 24 |
KCSG ST06-14 |
Invest New Drugs. 2011 Apr;29(2):366-73 |
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. |
|
| 23 |
KCSG ST05-05 |
Int J Clin Oncol. 2008 Jun;13(3):201-5 |
Chemotherapy for advanced gastric cancer: ongoing phase III study of S-1 alone versus S-1 and docetaxel combination (JACCRO GC03 study). |
|
| 22 |
KCSG BR06-01 |
Breast Cancer Res Treat. 2011 Jan;125(1):99-106. |
Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01). |
|
| 21 |
KCSG HB06-06 |
Cancer Chemother Pharmacol. 2010 Mar;65(4):641-7 |
Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial. |
|
| 20 |
NA |
Cancer Res Treat. 2008 Jun;40(2):87-92 |
Discrepant views of Korean medical oncologists and cancer patients on complementary and alternative medicine. |
|
| 19 |
KCSG CO05-01 |
Cancer Chemother Pharmacol. 2009 Sep;64(4):657-63 |
Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study. |
|
| 18 |
KCSG LU05-03 |
Clin Cancer Res. 2010 Feb 15;16(4):1307-14 |
Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. |
|
| 17 |
KCSG ST05-01 |
Cancer Chemother Pharmacol. 2009 May;63(6):1083-90 |
A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer. |
|
| 16 |
KCSG ST05-02 |
Asia Pac J Clin Oncol. 2009;5(1):46?54 |
Phase II study of S-1 and irinotecan combination chemotherapy as a first-line therapy for patients with advanced gastric cancer. Korean Cancer Study Group Protocol ST05-02 |
|
| 15 |
KCSG LU05-01 |
J Thorac Oncol. 2009;4(9):1136-43 |
Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group. |
|
| 14 |
KCSG LU05-02 |
Clin Cancer Res. 2008;14(12):3860-6 |
Are There Any Ethnic Differences in Molecular Predictors of Erlotinib Efficacy in Advanced Non-Small Cell Lung Cancer? |
|
| 13 |
KCSG LY04-03 |
Oncologist. 2014 Nov;19(11):1129-30 |
A phase II study of ifosfamide, methotrexate, etoposide, and prednisolone for previously untreated stage I/II extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial of the Korean Cancer Study Group. |
|
| 12 |
KCSG ST04-01 |
Jpn J Clin Oncol. 2007 Jul;37(7):501-8 |
Phase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer: Korea Japan Collaborative Study Group Trial. |
|
| 11 |
IRB04-01 |
Asia Pac J Clin Oncol. 2014 Mar;10(1):38-52 |
Registry of gastric cancer treatment evaluation (REGATE): I baseline disease characteristics |
|
| 10 |
KCSG HB03-01 |
Cancer Chemother Pharmacol. 2008 Oct;62(5):763-8 |
A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer. |
|
| 9 |
KCSG ST03-03 (KCSG 03-06-25) |
Cancer Chemother Pharmacol. 2008 Jul;62(2):263-70 |
Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study. |
|
| 8 |
KCSG LU02-01 (KCSG 02-09-17) |
J Clin Oncol. 2007;25:5233-9 |
Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. |
|
| 7 |
KCSG 02-11-08 |
Cancer Chemother Pharmacol. 2008 Jan;61(1):47-52 |
Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. |
|
| 6 |
KCSG ST02-01 (KCSG 02-10-31) |
Cancer Res Treat. 2009;41(1):12-8 |
Randomized, Multicenter, Phase III Trial of Heptaplatin 1-hour Infusion and 5-Fluorouracil Combination Chemotherapy Comparing with Cisplatin and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric Cancer |
|
| 5 |
KCSG CO01-01 (KCSG 01-11-17) |
Acta Oncol. 2005;44(3):230-5 |
Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial. |
|
| 4 |
KCSG BR01-01 (KCSG 01-10-05) |
Oncol Rep. 2005 Aug;14(2):481-7 |
Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor. |
|
| 3 |
N/A |
Ann Oncol. 2008 Aug;19(8):1477-84 |
Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. |
|
| 2 |
N/A |
Lung Cancer. 2006 Apr;52(1):75-81 |
Randomized phase II study of gemcitabine plus cisplatin versus etoposide plus cisplatin for the treatment of locally advanced or metastatic non-small cell lung cancer: Korean Cancer Study Group experience. |
|
| 1 |
N/A |
Cancer Res Treat. 2014;46(2):141-147 |
Clinical features and treatment of collecting duct carcinoma of the kidney from the korean cancer study group genitourinary and gynecology cancer committee. |
|
